Insider · CIK 0001373110
Mark J Gergen
chairofficerdirectorceopresident
Files at PSTX (Poseida Therapeutics, Inc.). First filing Nov 27, 2024, latest Dec 11, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $562k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Poseida Therapeutics, Inc. | $284k 30,000 shares | -4% | - | |
| 0Weak | Poseida Therapeutics, Inc. | $278k 30,000 shares | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | UTender of shares Common Stock | -636,726 | - | - | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -240,721 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -48,115 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -75,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -342,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -518,500 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -364,060 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -172,600 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 2, 2025 | PSTX Poseida Therapeutics, Inc. | FTax withholding Common Stock | -23,313 | $9.60 | $224k | 630,726 | Jan 3, 2025 |
| Dec 10, 2024 | PSTX Poseida Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +30,000 | $2.78 | $83k | 681,291 | Dec 11, 2024 |
| Dec 10, 2024 | PSTX Poseida Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -30,000 | $9.46 | $284k | 651,291 | Dec 11, 2024 |
| Dec 10, 2024 | PSTX Poseida Therapeutics, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 96,372 | Dec 11, 2024 |
| Nov 26, 2024 | PSTX Poseida Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +30,000 | $2.78 | $83k | 681,291 | Nov 27, 2024 |
| Nov 26, 2024 | PSTX Poseida Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -30,000 | $9.27 | $278k | 651,291 | Nov 27, 2024 |
| Nov 26, 2024 | PSTX Poseida Therapeutics, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 126,372 | Nov 27, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.